Leigh A. Vosseller - 30 May 2025 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
05 Jun 2025, 17:30:32 UTC
Prior SEC filing
19 May 2025
Next SEC filing
11 Aug 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Rachel Malina, Attorney-in-Fact for Leigh A. Vosseller

Key filing fact

Leigh A. Vosseller filed Form 4 for TANDEM DIABETES CARE INC (TNDM) on 05 Jun 2025.

Key facts

  • This page summarizes Leigh A. Vosseller's Form 4 filing for TANDEM DIABETES CARE INC (TNDM).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 05 Jun 2025, 17:30.

Change

  • Previous filing in this sequence was filed on 19 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001726322 Primary reporting owner

Vosseller Leigh

Relationship
EVP & CHIEF FINANCIAL OFFICER
Address
12400 HIGH BLUFF DRIVE, SAN DIEGO
Signature
/s/ Rachel Malina, Attorney-in-Fact for Leigh A. Vosseller
Signature date
05 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNDM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
33,798
Date
30 May 2025
Ownership
Direct
TNDM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
11,860
Date
30 May 2025
Ownership
Leigh A. Vosseller Trust
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNDM transaction Derivative

Performance Stock Unit

Award

Transaction value
$0
Shares
+31,486
Change %
Price
$0.000000
Shares after
31,486
Date
30 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
31,486
Exercise price
Footnotes
F2, F3
TNDM transaction Derivative

Restricted Stock Unit

Award

Transaction value
$0
Shares
+31,488
Change %
Price
$0.000000
Shares after
31,488
Date
30 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
31,488
Exercise price
Footnotes
F2, F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The securities are held by the Leigh A. Vosseller Trust dated January 17, 2010, of which Leigh Vosseller is the Trustee.

Footnote F2

Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

Footnote F3

Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Footnote F4

Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

Footnote F5

RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .